` LIPO (Lipella Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

L
LIPO
vs
S&P 500

Over the past 12 months, LIPO has underperformed S&P 500, delivering a return of -79% compared to the S&P 500's +14% growth.

Stocks Performance
LIPO vs S&P 500

Loading
LIPO
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
LIPO vs S&P 500

Loading
LIPO
S&P 500
Difference
www.alphaspread.com

Performance By Year
LIPO vs S&P 500

Loading
LIPO
S&P 500
Add Stock

Competitors Performance
Lipella Pharmaceuticals Inc vs Peers

S&P 500
LIPO
ABBV
CYTH
AMGN
GILD
Add Stock

Lipella Pharmaceuticals Inc
Glance View

Market Cap
3.4m USD
Industry
Biotechnology

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10 and LP-310. LP-10 is its proprietary formulation of tacrolimus and is optimized for local delivery to the urinary bladder. LP-310, another proprietary formulation of tacrolimus, is optimized for delivery to the oral mucosa (the tissue lining the walls inside the mouth) and tongue surface. The company is developing LP-310 for the treatment of oral lichen planus (OLP), a chronic inflammatory condition affecting the mucous membranes inside the mouth. The company has developed a proprietary technology, referred to as its Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces. Its Platform includes proprietary drug delivery technologies optimized for use with epithelial tissues.

LIPO Intrinsic Value
0.86 USD
Undervaluation 13%
Intrinsic Value
Price
L
Back to Top